Table 2.
Onset Symptoms, Laboratory Findings, and Treatments of Seven Patients With COVID-19
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | |
|---|---|---|---|---|---|---|---|
| Symptoms | |||||||
| Fever | Yes (>39°C) | Yes (>39°C) | Yes (>39°C) | Yes (>39°C) | Yes (>39°C) | Yes (>38°C) | Yes (>39°C) |
| Short of breath | + | + | + | + | + | − | − |
| Dry cough | − | + | − | − | + | + | + |
| Productive cough | + | − | − | − | − | − | − |
| Dyspnea | − | − | − | − | − | − | − |
| Myalgia | + | − | − | − | + | − | − |
| Palpitation | − | − | + | − | − | − | − |
| Fatigue | − | − | − | + | − | + | − |
| Diarrhea | − | − | − | − | − | − | + |
| Hospital stay before the operation (d) | 8 | 10 | 10 | 3 | 5 | 7 | 7 |
| Onset of symptoms (postop day) | 0 | 7 | 23 | 10 | 3 | 7 | 10 |
| Laboratory findings | |||||||
| First RT-PCR test for SARS-CoV-2 (postop day) | 4 | 15 | 34 | 13 | 12 | 12 | 15 |
| Positive RT-PCR for SARS-CoV-2 (postop day) | 4 | 15 | 39 | 13 | 12 | 12 | 20 |
| Respiratory pathogensa | NA | NA | Positive IgM to CP and MP | Negative | Negative | Negative | Negative |
| Leukocyte, ×109/liter | 10.09 | 5.52 | 2.93 | 6.56 | 5.24 | 3.13 | 6.86 |
| Neutrophils, ×109/liter | 8.23 | 3.8 | 1.7 | 4.83 | 4.3 | 1.63 | 5.01 |
| Lymphocytes (initial, minimum), ×109/liter | I: 0.89 M: 0.18 |
I: 1.12 M: 0.47 |
I: 0.6 M: 0.29 |
I: 1.03 M: 0.68 |
I: 0.53 M: 0.39 |
I: 1.14 M: 1.03 |
I: 1.06 M: 0.26 |
| Monocytes, ×109/liter | 0.96 | 0.5 | 0.63 | 0.63 | 0.35 | 0.34 | 0.79 |
| Hemoglobin, g/liter | 128 | 122 | 120 | 135 | 117 | 106 | 125 |
| Platelet count, ×10⁹/liter | 227 | 225 | 148 | 220 | 188 | 191 | 210 |
| Procalcitonin, ng/mL | 0.22 | 0.06 | 0.08 | 0.09 | 0.09 | 0.06 | 0.05 |
| High-sensitivity C-reactive protein, mg/liter | 164.9 | 25.5 | 149 | 67.3 | 55.5 | 11.9 | 46.4 |
| Alanine transaminase | 13 | 196 | 18 | 38 | 31 | 27 | 13 |
| Aspartate aminotransferase | 31 | 186 | 28 | 23 | 47 | 42 | 17 |
| Total bilirubin, μmol/liter | 9.9 | 9.2 | 5.7 | 8.3 | 9.4 | 4.7 | 5 |
| Albumin, g/liter | 30.8 | 38 | 31.5 | 38.2 | 35 | 31.8 | 36.2 |
| Creatinine, μmol/liter | 70 | 54 | 50 | 63 | 54 | 61 | 49 |
| Prothrombin time, s | 12.7 | 12.1 | 12.3 | 14.8 | 13.5 | 13.4 | 13.7 |
| Activated partial thromboplastin time, s | 57.8 | 42.3 | 43.2 | 34.7 | 44.6 | 38.7 | 47.7 |
| D-dimers, μg/mL | 2.25 | 1.90 | 3.21 | 5.70 | 1.08 | 1.01 | 4.58 |
| Treatments | |||||||
| Intravenous antibiotics | + | + | + | + | + | + | + |
| Antivirus therapy | Oseltamivir | Oseltamivir | Oseltamivir | Oseltamivir Lopinavir Ritonavir |
Oseltamivir Umifenovir |
Oseltamivir | Oseltamivir Umifenovir |
| Systemic corticosteroids | − | + | − | + | + | − | + |
| Intravenous immunoglobin | − | − | − | + | + | − | + |
| Oxygen therapy | + | + | + | + | + | + | + |
| Mechanical ventilation | BiPAP | − | IMV | − | − | − | IMV |
| ECMO | − | − | − | − | − | − | − |
| ICU | + | − | + | − | − | − | + |
| Clinical outcomes | Died | Discharged | Died | In hospital | In hospital | Discharged | Died |
| Days since the onset of symptoms to the outcome event | 5 | 32 | 19 | NA | NA | 33 | 25 |
BiPAP, bilevel positive airway pressure; COVID-19, coronavirus disease 2019; CP, Chlamydophila pneumoniae; ECMO, extracorporeal membrane oxygenation; I, initial; ICU, intensive care unit; IgM, immunoglobulin M; IMV, invasive mechanical ventilation; M, minimum; MP, Mycoplasma pneumoniae; NA, not available; postop day, postoperation day; RT-PCR, reverse-transcriptase polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Respiratory pathogens in our study include respiratory syncytial virus, adenovirus, influenza A, influenza B, parainfluenza virus, Legionella pneumophila, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.